A Phase 1, Open‐Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects. Issue 7 (5th March 2022)
- Record Type:
- Journal Article
- Title:
- A Phase 1, Open‐Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects. Issue 7 (5th March 2022)
- Main Title:
- A Phase 1, Open‐Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects
- Authors:
- Trivedi, Ashit
Mather, Omar
Vega, Silvia
Hutton, Shauna
Hellawell, Jennifer
Lee, Edward - Abstract:
- Abstract: This phase 1, open‐label study evaluated the effect of food and administration of the cytochrome P450 3A4 and P‐glycoprotein inhibitor itraconazole (ITZ) on the pharmacokinetics of AMG 986. In cohort 1, 12 healthy subjects received a single oral dose of AMG 986 200 mg ± food on days 1 and 10. In cohort 2, 15 healthy subjects received oral ITZ 200 mg once daily on days 8 to 15 and a single oral dose of AMG 986 10 mg on days 1 and 11. The geometric least squares mean ratios of fed/fasted for AMG 986 maximum observed concentration (Cmax ) and area under the plasma concentration–time curve from time 0 to infinity (AUCinf ) were 0.76 (90%CI, 0.61‐0.95) and 1.07 (90%CI, 0.94‐1.22), respectively. The geometric least squares mean ratios of AMG 986 10 mg plus ITZ 200 mg/AMG 986 10 mg alone for AMG 986 Cmax and AUCinf were 1.36 (90%CI, 1.25‐1.48) and 5.13 (90%CI, 4.71‐5.59), respectively. Overall, 3 subjects experienced mild treatment‐related adverse events; there were no serious or fatal adverse events. In conclusion, food had no apparent effect on the exposure of AMG 986 200 mg; therefore, food restrictions are not required. Potent cytochrome P450 3A4 and/or P‐glycoprotein inhibitors may warrant AMG 986 dose reduction and should be coadministered with caution in patients with heart failure treated with AMG 986.
- Is Part Of:
- Clinical pharmacology in drug development. Volume 11:Issue 7(2022)
- Journal:
- Clinical pharmacology in drug development
- Issue:
- Volume 11:Issue 7(2022)
- Issue Display:
- Volume 11, Issue 7 (2022)
- Year:
- 2022
- Volume:
- 11
- Issue:
- 7
- Issue Sort Value:
- 2022-0011-0007-0000
- Page Start:
- 849
- Page End:
- 856
- Publication Date:
- 2022-03-05
- Subjects:
- AMG 986 -- apelin -- food effect -- itraconazole -- pharmacokinetics -- safety
Drugs -- Testing -- Periodicals
Drug development -- Periodicals
Clinical pharmacology -- Periodicals
615.580724 - Journal URLs:
- http://cpd.sagepub.com ↗
http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%292160-7648 ↗
http://accp1.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2160-7648/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cpdd.1074 ↗
- Languages:
- English
- ISSNs:
- 2160-7648
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330300
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22277.xml